Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.71 |
| ▸ | DHFR | P00374 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453326 | 1.00 | SLC6A3 (0.71) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL14601979 | 1.00 | SLC6A3 (0.71) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL26840808 | 1.00 | SLC6A3 (0.71) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL14602065 | 1.00 | SLC6A3 (0.71) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL26720835 | 1.00 | SLC6A3 (0.71) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL23459443 | 0.95 | SLC6A3 (0.63) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL19574769 | 0.95 | SLC6A3 (0.63) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL26720612 | 0.89 | SLC6A3 (0.54) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10326815 | 0.85 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL729266 | 0.85 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-7851487-B2 | Use of tetrahydropyridines in the treatment of central nervous system disorders | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2010-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | SLC6A3 3986/4885SLC6A2 4256/4885SLC6A4 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.